Vascular cognitive impairment (VCI) is the second most common type of dementia after Alzheimer's disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
29,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The collected articles were categorized into studies related to 6 systems or disease types: motor system (17 articles), metabolic system (110 articles), cardiocerebral vascular system (171 articles), nervous system (71 articles), urinary system (2 articles), and cancer (21 articles). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The prevalence of dementia has substantially increased worldwide. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
As patients lose cognitive function, they lose autonomy and increasingly use fiscal, social, and medical resources. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
39/100
The societal value of strategies that delay the onset and progression of dementia cannot be overstated. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Engaging in targeted exercise interventions is a promising, non-pharmacological strategy to mitigate the deleterious effects of aging and disease on brain health. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Physical activity and exercise have become a central component of medical management of chronic illness, particular for the elderly who suffer from neurodegenerative disorders that impair their cognition and mobility. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A significant body of evidence supports the protective role of exercise training (ET) in cardiovascular diseases, skeletal muscle dystrophies, several types of cancer, Alzheimer disease or even in the recovery of spinal cord injury. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The number of adults with Alzheimer's disease (AD) or related dementia is expected to increase exponentially. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
39/100
Present demographic changes demonstrate that the number of elderly people is growing at a frenetic pace. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Frailty syndrome encompasses several physical hallmarks such as loss of muscle strength, power output and mass, which leads to poor gait ability, fatigue, falls and overall difficulty to perform activities of daily living. 1 key finding →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Dementias, and Alzheimer's disease (AD) in particular, will increasingly become a public health issue. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia is increasing in Australia in line with population ageing and is expected to peak by mid-century. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Increased age is associated with normative declines in both sleep and cognitive functioning. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The endogenous circadian rhythms are one of the cardinal processes that control sleep. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Insomnia is a common problem in older people, especially in patients with mild cognitive impairment (MCI) whose circadian rhythm is often compromised. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Disruptions of sleep and circadian rhythms are among the most debilitating symptoms in patients with neurodegenerative diseases. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep problems occur commonly in normal and pathologic aging. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep and wakefulness disorders are commonly seen in patients with Parkinson's disease, Lewy body dementia and Alzheimer's disease. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
39/100
We found that tau phosphorylation undergoes sleep-driven circadian variations as it is hyperphosphorylated during sleep but not during acute sleep deprivation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cerebrospinal fluid (CSF) is a fluidic part of the brain's microenvironment that isolates the brain from the rest of the body. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mutations in fused in sarcoma (Fus) cause familial amyotrophic lateral sclerosis (ALS) and occasionally frontotemporal dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep disturbances such as insomnia, hypersomnia, and circadian rhythm disturbance are common in normal elderly and Alzheimer's disease (AD) patients. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The article reviews the phenomenology of sleep and wakefulness disorders in Parkinson's disease and Alzheimer's disease. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD), which accounts for most of the dementia cases, is, aside from cognitive deterioration, often characterized by the presence of non-cognitive symptoms. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
From across this tag
10 of the 1,962 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Physical activity, biomarkers of brain pathologies and dementia risk: Results from the Memento clinical cohort
- Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: micronutrients
- Diet-wide analyses for risk of colorectal cancer: prospective study of 12,251 incident cases among 542,778 women in the UK
- Whole Dietary Patterns, Cognitive Decline and Cognitive Disorders: A Systematic Review of Prospective and Intervention Studies
- South Korean Study to Prevent Cognitive Impairment and Protect Brain Health Through Lifestyle Intervention in At-Risk Elderly People: Protocol of a Multicenter, Randomized Controlled Feasibility Trial
- Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease
- Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology
- The Effect of Multidomain Lifestyle Intervention on Daily Functioning in Older People
- The Influence of Lifestyle on Cognitive Function and Quality of Life in People with Dementia
- Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 29,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,380 records, built mostly from automated pulls of Europe PMC (63.3% of the library) and OpenAlex (17.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →